Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Renal Cell 9Prostatic Neoplasms 8Urinary Bladder Neoplasms 7Melanoma 7Neoplasms 5Head and Neck Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Colorectal Neoplasms 3Carcinoma, Merkel Cell 3Squamous Cell Carcinoma of Head and Neck 2Kidney Neoplasms 2Colonic Neoplasms 2Carcinoma, Hepatocellular 2Uveal Melanoma 1Uterine Neoplasms 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma 1Recurrence 1Penile Neoplasms 1Mesothelioma, Malignant 1Lymphoma, Non-Hodgkin 1

Interventions

pembrolizumab 9Nivolumab 6Magnetic Resonance Spectroscopy 3Gemcitabine 3Fluorodeoxyglucose F18 3Cisplatin 3Paclitaxel 2Ipilimumab 2Fluorouracil 2FAPI-46 2Drug Therapy 2Carboplatin 2Bevacizumab 2zenocutuzumab 1ulixertinib 1tislelizumab 1spartalizumab 1seribantumab 1niraparib 1milademetan 1lenvatinib 1entrectinib 1durvalumab 1cemiplimab 1atezolizumab 1alectinib 1abemaciclib 1Specimen Handling 1Ramucirumab 1Quality of Life 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × cemiplimab × Genitourinary × Clear all
NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

University of Pittsburgh

Phase 3 Completed
161 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡